Bernhard Hoffmann - 28 Jan 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Reporting relationship: VP of Corp. Dev. & Ops & Sec.
Issuer ticker: IRD
Reported as of: 28 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Feb 2022, 15:29:46 UTC
Next SEC filing: 12 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Kuras, by Power of Attorney

Key filing fact

Bernhard Hoffmann filed Form 4 for Ocuphire Pharma, Inc. (IRD) on 01 Feb 2022.

Key facts

This page summarizes Bernhard Hoffmann's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Feb 2022, 15:29.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUP transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +42,500
Change %
Price: $0.000000
Shares after: 42,500
Date: 28 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,500
Exercise price: $2.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest with respect to 10,625 shares on January 28, 2023, and then with respect to 885 shares on the last day of each month from February 2023 through December 2025 and with respect to 900 shares at the end of January 2026.